5W2E

HCV NS5B RNA-dependent RNA polymerase in complex with non-nucleoside inhibitor MK-8876

5W2E の概要

• エントリーDOI: 10.2210/pdb5w2e/pdb
• 分子名称: Genome polyprotein, 2-(4-fluorophenyl)-5-(11-fluoro-6H-pyrido[2',3':5,6][1,3]oxazino[3,4-a]indol-2-yl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide (3 entities in total)
• 機能のキーワード: antiviral inhibitor, hcv, polymerase, viral protein, transferase-inhibitor complex, transferase/inhibitor
• 由来する生物種: Hepatitis C virus genotype 1b (isolate BK) (HCV)
• 細胞内の位置: Core protein p21: Host endoplasmic reticulum membrane; Single-pass membrane protein. Core protein p19: Virion . Envelope glycoprotein E1: Virion membrane ; Single-pass type I membrane protein . Envelope glycoprotein E2: Virion membrane ; Single-pass type I membrane protein . p7: Host endoplasmic reticulum membrane ; Multi-pass membrane protein . Protease NS2-3: Host endoplasmic reticulum membrane ; Multi-pass membrane protein . Serine protease NS3: Host endoplasmic reticulum membrane ; Peripheral membrane protein . Non-structural protein 4A: Host endoplasmic reticulum membrane ; Single-pass type I membrane protein . Non-structural protein 4B: Host endoplasmic reticulum membrane ; Multi-pass membrane protein . Non-structural protein 5A: Host endoplasmic reticulum membrane ; Peripheral membrane protein . RNA-directed RNA polymerase: Host endoplasmic reticulum membrane ; Single-pass type I membrane protein : P26663
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 129368.01

構造登録者

Lesburg, C.A.,Ummat, A. (登録日: 2017-06-06, 公開日: 2017-08-16, 最終更新日: 2023-10-04)

主引用文献

McComas, C.C.,Palani, A.,Chang, W.,Holloway, M.K.,Lesburg, C.A.,Li, P.,Liverton, N.,Meinke, P.T.,Olsen, D.B.,Peng, X.,Soll, R.M.,Ummat, A.,Wu, J.,Wu, J.,Zorn, N.,Ludmerer, S.W.
Development of a New Structural Class of Broadly Acting HCV Non-Nucleoside Inhibitors Leading to the Discovery of MK-8876.
ChemMedChem, 12:1436-1448, 2017

PubMed Abstract: Studies directed at developing a broadly acting non-nucleoside inhibitor of HCV NS5B led to the discovery of a novel structural class of 5-aryl benzofurans that simultaneously interact with both the palm I and palm II binding regions. An initial candidate was potent in vitro against HCV GT1a and GT1b replicons, and induced multi-log reductions in HCV viral load when orally dosed to chronic GT1 infected chimpanzees. However, in vitro potency losses against clinically relevant GT1a variants prompted a further effort to develop compounds with sustained potency across a broader array of HCV genotypes and mutants. Ultimately, a biology and medicinal chemistry collaboration led to the discovery of the development candidate MK-8876. MK-8876 demonstrated a pan-genotypic potency profile and maintained potency against clinically relevant mutants. It demonstrated moderate bioavailability in rats and dogs, but showed low plasma clearance characteristics consistent with once-daily dosing. Herein we describe the efforts which led to the discovery of MK-8876, which advanced into Phase 1 monotherapy studies for evaluation and characterization as a component of an all-oral direct-acting drug regimen for the treatment of chronic HCV infection.

PubMed: 28741898
DOI: 10.1002/cmdc.201700228

実験手法

X-RAY DIFFRACTION (2.8 Å)